Market Outlook

The treatment armamentarium of mCRPC has significantly evolved with the addition of hormonal agents such as Zytiga (Johnson & Johnson/Janssen) and Xtandi (Medivation/Astellas Pharma). These targeted therapies have benefited efficacy outcome and offer favorable safety profiles. The management of mCRPC has been further transformed with the availability of therapeutic vaccine Provenge (Valeant) and radiopharmaceutical agent Xofigo (Bayer HealthCare). Nevertheless, an enormous  unmet need exists for better-tolerated novel therapies that could prolong overall survival and, to a greater extent, delay disease progression. Our unmet need module analyzes the key drivers of prescribing and identifies the most attractive commercial opportunities for drug developers.

Questions Answered

  • What are the treatment drivers and goals for mCRPC?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities for drug developers?
  • How do current therapies perform on key treatment drivers and goals for mCRPC?
  • What are the prevailing areas of unmet need and opportunity in mCRPC?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new first-line mCRPC therapy?

Product Description

Unmet Need provides quantitative insight into U.S. and European physicians’ perception of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, and the United Kingdom.

Primary research: Survey of 61 U.S. and 31 European medical oncologists fielded in August 2018.

Key companies:  Johnson & Johnson/Janssen, Medivation/Astellas, Valeant, Bayer HealthCare, and Sanofi.

Key drugs: Zytiga, Xtandi, Provenge, Xofigo, and Jevtana.

Table of contents

  • Detailed, Expanded Analysis (US/EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Metastatic Castrate-Resistant Prostate Cancer
      • Key Findings: Unmet Need in Metastatic Castrate-Resistant Prostate Cancer and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Metastatic Castrate-Resistant Prostate Cancer Market and Emerging Therapy Insights
        • Opportunity: A New Therapy with Improved Overall Survival
        • Opportunity: A New Therapy That Delays Disease Progression
        • Opportunity: A New Therapy That Can Improve Bone Metastases-Related Pain
        • Opportunity: A New Therapy with Improved Safety and Tolerability Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • First-Line Metastatic Castrate-Resistant Prostate Cancer Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Author(s): Sudha Malhotra, Ph.D

Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.

Related Reports

Prostate Cancer | Landscape & Forecast | Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga...

View Details

Prostate Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Hormonal therapies have dominated the treatment of prostate cancer for the past decade. Zytiga (Janssen, generics) and Xtandi (Medivation / Astellas Pharma), initially approved for metastatic cas...

View Details

Prostate Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key prostate cancer patie...

View Details

Prostate Cancer | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into...

View Details